Background Hepatitis B virus infection is closely related to hepatocellular carcinoma （HCC）. Cyclooxygenase-2 （COX-2） is overexpressed in HCC and considered to play a role in hepatic carcinogenesis. In this study,...Background Hepatitis B virus infection is closely related to hepatocellular carcinoma （HCC）. Cyclooxygenase-2 （COX-2） is overexpressed in HCC and considered to play a role in hepatic carcinogenesis. In this study, we analyzed the polymorphism of COX-2 promoter -899G/C in healthy controls, chronic hepatitis B （CHB） patients, liver cirrhosis patients, and hepatocellular carcinoma （HCC） patients, to investigate the relationship between COX-2 -899G/C polymorphism and the risk for hepatitis B-related liver cancer in a Chinese population from Gansu province. Methods Patients were divided into four groups： 300 patients with CHB, 300 patients with liver cirrhosis, 300 patients with HCC, and 300 healthy controls. The polymorphism of COX-2 -899G/C was detected by PCR-TaqMan probes. The results were analyzed by SPSS 17.0. Results The COX-2 -899G/C genotypes were GG, GC, and CC. Frequencies in CHB were 87.00%, 12.67%, 0.33%; in liver cirrhosis were 85.33%, 14.00%, 0.67%; in HCC were 77.00%, 21.67%, 1.33%; and in healthy controls were 90.67%, 9.00%, 0.33%, respectively. COX-2 -899C carriers may have an increased risk for hepatitis B-related liver cancer. Compared with the frequency of GG genotype, there were significant differences in the frequency of GC genotype between HCC and healthy control groups （0R=2.835, 95%C/： 1.751-4.589）; HCC and CHB groups （OR=1.933, 95%C/： 1.248-2.994）; and HCC and liver cirrhosis groups （OR=1. 175, 95%C/： 1.119-2.628）. Stratification analyses showed that COX-2 -899C allele carriers with a drinking history are more susceptible to develop HCC. Conclusion COX-2 -899C genotype may increase the susceptibility of individuals to hepatitis B-related liver cancer in Gansu province, China.展开更多
目的探讨乙肝相关性肝癌(HCC)患者术前HBV-DNA载量水平与术后肝功能恢复的关系。方法将56例行肝癌根治术的HCC患者按术前血清中HBV-DNA载量分为低复制组(血清HBV-DNA载量≤104IU/ml,n=35)和高复制组(血清HBV-DNA载量≥105IU/ml,n=21),...目的探讨乙肝相关性肝癌(HCC)患者术前HBV-DNA载量水平与术后肝功能恢复的关系。方法将56例行肝癌根治术的HCC患者按术前血清中HBV-DNA载量分为低复制组(血清HBV-DNA载量≤104IU/ml,n=35)和高复制组(血清HBV-DNA载量≥105IU/ml,n=21),观察比较术前3 d和术后7 d HBV-DNA载量变化例数及ALT、AST、ALB、TBIL等肝功能指标变化、肝功能恢复时间,同时记录两组患术后并发症发生情况。结果两组患者手术前、后血清中HBV-DNA载量无显著性变化(P>0.05),两组患者术后7 d ALT、AST、TBIL指标较术前3 d显著升高(P<0.05),而三组术后ALB指标较治疗前显著降低(P<0.05),且高复制组ALT、AST指标显著高于低复制组(P<0.05),而两组在ALB和ABIL等指标比较,差异不具有统计学意义(P>0.05)。而低复制组肝功能恢复天数显著短于高复制组,差异具有统计学意义(P<0.05)。高复制组患者术后并发症(47.62%)显著高于低复制组患者(17.14%),差异具有统计学意义(P<0.05)。结论 HCC患者术前血清HBV-DNA的高水平载量将显著延长患者术后肝功能恢复时间,同时增加患者术后并发症发生风险。展开更多
文摘Background Hepatitis B virus infection is closely related to hepatocellular carcinoma （HCC）. Cyclooxygenase-2 （COX-2） is overexpressed in HCC and considered to play a role in hepatic carcinogenesis. In this study, we analyzed the polymorphism of COX-2 promoter -899G/C in healthy controls, chronic hepatitis B （CHB） patients, liver cirrhosis patients, and hepatocellular carcinoma （HCC） patients, to investigate the relationship between COX-2 -899G/C polymorphism and the risk for hepatitis B-related liver cancer in a Chinese population from Gansu province. Methods Patients were divided into four groups： 300 patients with CHB, 300 patients with liver cirrhosis, 300 patients with HCC, and 300 healthy controls. The polymorphism of COX-2 -899G/C was detected by PCR-TaqMan probes. The results were analyzed by SPSS 17.0. Results The COX-2 -899G/C genotypes were GG, GC, and CC. Frequencies in CHB were 87.00%, 12.67%, 0.33%; in liver cirrhosis were 85.33%, 14.00%, 0.67%; in HCC were 77.00%, 21.67%, 1.33%; and in healthy controls were 90.67%, 9.00%, 0.33%, respectively. COX-2 -899C carriers may have an increased risk for hepatitis B-related liver cancer. Compared with the frequency of GG genotype, there were significant differences in the frequency of GC genotype between HCC and healthy control groups （0R=2.835, 95%C/： 1.751-4.589）; HCC and CHB groups （OR=1.933, 95%C/： 1.248-2.994）; and HCC and liver cirrhosis groups （OR=1. 175, 95%C/： 1.119-2.628）. Stratification analyses showed that COX-2 -899C allele carriers with a drinking history are more susceptible to develop HCC. Conclusion COX-2 -899C genotype may increase the susceptibility of individuals to hepatitis B-related liver cancer in Gansu province, China.
文摘目的探讨乙肝相关性肝癌(HCC)患者术前HBV-DNA载量水平与术后肝功能恢复的关系。方法将56例行肝癌根治术的HCC患者按术前血清中HBV-DNA载量分为低复制组(血清HBV-DNA载量≤104IU/ml,n=35)和高复制组(血清HBV-DNA载量≥105IU/ml,n=21),观察比较术前3 d和术后7 d HBV-DNA载量变化例数及ALT、AST、ALB、TBIL等肝功能指标变化、肝功能恢复时间,同时记录两组患术后并发症发生情况。结果两组患者手术前、后血清中HBV-DNA载量无显著性变化(P>0.05),两组患者术后7 d ALT、AST、TBIL指标较术前3 d显著升高(P<0.05),而三组术后ALB指标较治疗前显著降低(P<0.05),且高复制组ALT、AST指标显著高于低复制组(P<0.05),而两组在ALB和ABIL等指标比较,差异不具有统计学意义(P>0.05)。而低复制组肝功能恢复天数显著短于高复制组,差异具有统计学意义(P<0.05)。高复制组患者术后并发症(47.62%)显著高于低复制组患者(17.14%),差异具有统计学意义(P<0.05)。结论 HCC患者术前血清HBV-DNA的高水平载量将显著延长患者术后肝功能恢复时间,同时增加患者术后并发症发生风险。
